Blood-brain barrier pharmacoproteomics-based reconstruction of the in vivo brain distribution of P-glycoprotein substrates in cynomolgus monkeys

Journal of Pharmacology and Experimental Therapeutics

Volumn 350, Issue 3, 2014, Pages 578-588

  Uchida, Yasuo ^a   Wakayama, Kentaro ^b   Ohtsuki, Sumio ^c   Chiba, Masato ^b   Ohe, Tomoyuki ^b   Ishii, Yasuyuki ^b   Terasaki, Tetsuya ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b BANYU PHARMACEUTICAL CO LTD   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DIAZEPAM; INDINAVIR; LOPERAMIDE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; QUINIDINE; VERAPAMIL;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG TRANSPORT; IN VITRO STUDY; IN VIVO STUDY; MACACA FASCICULARIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; SPECIES DIFFERENCE; TISSUE DISTRIBUTION; TRANSCYTOSIS;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; LLC-PK1 CELLS; LOPERAMIDE; MACACA FASCICULARIS; MALE; MICE; P-GLYCOPROTEIN; PACLITAXEL; PROTEIN BINDING; PROTEOMICS; SUBSTRATE SPECIFICITY; SWINE; TISSUE DISTRIBUTION;

EID: 84904979602     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.214536     Document Type: Article

References (32)

1. Adachi Y, Suzuki H, and Sugiyama Y (2001) Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res 18:1660-1668.
2. Carvalho-Silva B, Moreira-Campos LM, Nunan EA, Vianna-Soares CD, Araujo-Alves BL, Cesar IC, and Pianetti GA (2004) Optimization and statistical evaluation of dissolution tests for indinavir sulfate capsules. Farmaco 59:921-927.
3. Di L, Umland JP, Chang G, Huang Y, Lin Z, Scott DO, Troutman MD, and Liston TE (2011) Species independence in brain tissue binding using brain homogenates. Drug Metab Dispos 39:1270-1277.
4. Dyer J, Barker PJ, and Shirazi-Beechey SP (1997) Nutrient regulation of the intestinal Na+/glucose co-transporter (SGLT1) gene expression. Biochem Biophys Res Commun 230:624-629.
5. Feng B, Mills JB, Davidson RE, Mireles RJ, Janiszewski JS, Troutman MD, and de Morais SM (2008) in vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos 36:268-275.
6. Fridén M, Gupta A, Antonsson M, Bredberg U, and Hammarlund-Udenaes M (2007) in vitro methods for estimating unbound drug concentrations in the brain interstitial and intracellular fluids. Drug Metab Dispos 35:1711-1719.
7. Fridén M, Bergström F, Wan H, Rehngren M, Ahlin G, Hammarlund-Udenaes M, and Bredberg U (2011) Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods. Drug Metab Dispos 39:353-362.
8. Fukumoto H, Cheung BS, Hyman BT, and Irizarry MC (2002) Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol 59: 1381-1389.
9. Fuse E, Tanii H, Kurata N, Kobayashi H, Shimada Y, Tamura T, Sasaki Y, Tanigawara Y, Lush RD, and Headlee D, et al. (1998) Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. Cancer Res 58: 3248-3253.
10. Ghose AK, Viswanadhan VN, and Wendoloski JJ (1999) a knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. a qualitative and quantitative characterization of known drug databases. J Comb Chem 1:55-68.
11. Hendrikse NH, Schinkel AH, de Vries EG, Fluks E, Van der Graaf WT, Willemsen AT, Vaalburg W, and Franssen EJ (1998) Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br J Pharmacol 124:1413-1418.
12. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, Cascorbi I, Gerloff T, Roots I, and Eichelbaum M, et al. (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473-3478.
13. Hoshi Y, Uchida Y, Tachikawa M, Inoue T, Ohtsuki S, and Terasaki T (2013) Quantitative atlas of blood-brain barrier transporters, receptors, and tight junction proteins in rats and common marmoset. J Pharm Sci 102:3343-3355.
14. Ito K, Uchida Y, Ohtsuki S, Aizawa S, Kawakami H, Katsukura Y, Kamiie J, and Terasaki T (2011) Quantitative membrane protein expression at the blood-brain barrier of adult and younger cynomolgus monkeys. J Pharm Sci 100: 3939-3950.
15. Kakee A, Terasaki T, and Sugiyama Y (1996) Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier. J Pharmacol Exp Ther 277: 1550-1559.
16. Kamiie J, Ohtsuki S, Iwase R, Ohmine K, Katsukura Y, Yanai K, Sekine Y, Uchida Y, Ito S, and Terasaki T (2008) Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. Pharm Res 25:1469-1483.
17. Kola I and Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711-715.
18. Kpakima F, Palandra J, Buchholz L, Cherukury M, Gray D, Glase S, Dooley D, and El-Kattan A (2006) Significant species differences in the in vivo brain penetration of a CNS compound: a case study, in Proceedings of 2006 AAPS Annual Meeting and Exposition; 2006 Oct 22-Nov 2; San Antonio, TX. American Association of Pharmaceutical Scientists, Arlington, VA.
19. Kratochwil NA, Huber W, Müller F, Kansy M, and Gerber PR (2004) Predicting plasma protein binding of drugs - revisited. Curr Opin Drug Discov Devel 7: 507-512.
20. Kusuhara H and Sugiyama Y (2009) in vitro-in vivo extrapolation of transportermediated clearance in the liver and kidney. Drug Metab Pharmacokinet 24:37-52.
21. Langenfeld E, Zanger UM, Jung K, Meyer HE, and Marcus K (2009) Mass spectrometry-based absolute quantification of microsomal cytochrome P450 2D6 in human liver. Proteomics 9:2313-2323.
22. Ooie T, Terasaki T, Suzuki H, and Sugiyama Y (1997) Quantitative brain micro-dialysis study on the mechanism of quinolones distribution in the central nervous system. Drug Metab Dispos 25:784-789.
23. Pardridge WM (2002) Why is the global CNS pharmaceutical market so under-penetrated? Drug Discov Today 7:5-7.
24. Sankaranarayanan S, Holahan MA, Colussi D, Crouthamel MC, Devanarayan V, Ellis J, Espeseth A, Gates AT, Graham SL, and Gregro AR, et al (2009) First demonstration of cerebrospinal fluid and plasma a beta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates. J Pharmacol Exp Ther 328:131-140.
25. Shirasaka Y, Sakane T, and Yamashita S (2008) Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane. J Pharm Sci 97:553-565.
26. Syvänen S, Lindhe O, Palner M, Kornum BR, Rahman O, Långström B, Knudsen GM, and Hammarlund-Udenaes M (2009) Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. Drug Metab Dispos 37:635-643.
27. Tachibana T, Kitamura S, Kato M, Mitsui T, Shirasaka Y, Yamashita S, and Sugiyama Y (2010) Model analysis of the concentration-dependent permeability of P-gp substrates. Pharm Res 27:442-446.
28. Takeuchi T, Yoshitomi S, Higuchi T, Ikemoto K, Niwa S, Ebihara T, Katoh M, Yokoi T, and Asahi S (2006) Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1. Pharm Res 23:1460-1472.
29. Uchida Y, Ohtsuki S, Kamiie J, and Terasaki T (2011a) Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice. J Pharmacol Exp Ther 339:579-588.
30. Uchida Y, Ohtsuki S, Katsukura Y, Ikeda C, Suzuki T, Kamiie J, and Terasaki T (2011b) Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J Neurochem 117:333-345.
31. Uchida Y, Tachikawa M, Ohtsuki S, and Terasaki T (2014) Blood-Brain Barrier (BBB) Pharmacoproteomics: a New Research Field Opened Up by Quantitative Targeted Absolute Proteomics (QTAP), in Drug Delivery to the Brain (Hammarlund-Udenaes M, deLange EC, and Thorne RG, eds) pp 63-100, Springer, New York.
32. Yagi T and Ohkubo M (2010) Cost and time period for drug discovery and development. JPMA News Letter 136:33-35.